Biogen Inc. Equity-NMS: BIIB

Healthcare

Drug Manufacturers-General

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$218.2

52W high :

$351.86

1Y :

-36.03%

5Y :

-23.24%

EPS(TTM): :

13.97

Shares O/S :

145.11 M

Market cap :

31.57 B

What is the share price of Biogen Inc. today?

Biogen Inc. (BIIB) share price as of August 8, 2022, is $217.56. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Biogen Inc.?

Yes, Indian Investors can invest in the Biogen Inc. (BIIB) Share by opening an international trading account with Angel One.

How can I purchase Biogen Inc. shares in India?

Purchasing Biogen Inc. (BIIB) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Biogen Inc. (BIIB) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Biogen Inc.?

Yes, you can purchase fractional shares of Biogen Inc. (BIIB) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Biogen Inc.?

The market capitalization of Biogen Inc. on August 9, 2022, is $31.57 B.

In which sector Biogen Inc. belongs?

Biogen Inc. operates in the Healthcare sector, specifically in the Drug Manufacturers-General industry.

What documents are required to invest in Biogen Inc. stocks?

In order to invest in Biogen Inc. (BIIB) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.